Table of Contents for New Drug Futures: Anti-Infective Chapter
CURRENT MARKET SIZE 1
Antibiotic Sales 2
Antiviral Sales 2
Antifungal Sales 2
ADDRESSABLE PATIENT POPULATION 3
Bacterial Infections 3
Viral infections 3
Human Immunodeficiency Virus (HIV) 3
Hepatitis B (HBV) 4
Hepatitis C (HCV) 4
CURRENT TREATMENTS 5
Antibacterial Agents 6
Antiviral Agents- HIV 6
Antiviral Agents- HCV/HBV 7
ANTI-INFECTIVES SALES DRIVERS 8
ANTI-INFECTIVE SALES BREAKERS 10
FUTURE TREATMENTS 11
MARKET DYNAMICS - WINNERS & LOSERS 15
KEY DRUGS LAUNCHES BY 2010 16
KEY EVALUATION CRITERIA 17
KEY ANTI-INFECTIVES DRUG LAUNCHES BY 2010 18
Anidulafungin (Pfizer) 18
Novelty/rationale for mechanism of action 18
Proof of concept/clinical data 18
Management/clinical expertise 18
Competition within the marketplace/gaining share of voice 18
Risks associated with developing a drug within a therapeutic class 19
Filings and approval 19
Sales forecasts and assumptions 19
Competitor Ratio Analysis 19
Aptivus (Boehringer Ingelheim) 20
Novelty/rationale for mechanism of action 20
Proof of concept/clinical data 20
Management/clinical expertise 20
Competition within the marketplace/gaining share of voice 20
Risks associated with developing a drug within a therapeutic class 21
Filings and approval 21
Sales forecasts and assumptions 21
Competitor Ratio Analysis 21
Aplaviroc (GlaxoSmithKline) 22
Novelty/rationale for mechanism of action 22
Proof of concept/clinical data 22
Management/clinical expertise 22
Competition within the marketplace/gaining share of voice 22
Risks associated with developing a drug within a therapeutic class 23
Filings and approval 23
Sales forecasts and assumptions 23
Competitor Ratio Analysis 24
Ceftobiprole (Johnson & Johnson) 24
Novelty/rationale for mechanism of action 24
Proof of concept/clinical data 24
Management/clinical expertise 25
Competition within the marketplace/gaining share of voice 25
Risks associated with developing a drug within a therapeutic class 25
Filings and approval 25
Sales forecasts and assumptions 26
Competitor Ratio Analysis 26
Garenoxicin (Schering-Plough) 26
Novelty/rationale for mechanism of action 26
Proof of concept/clinical data 26
Management/clinical expertise 27
Competition within the marketplace/gaining share of voice 27
Risks associated with developing a drug within a therapeutic class 27
Filings and approval 27
Sales forecasts and assumptions 27
Competitor Ratio Analysis 28
GW695634 (GlaxoSmithKline) 28
Novelty/rationale for mechanism of action 28
Proof of concept/clinical data 28
Management/clinical expertise 28
Competition within the marketplace/gaining share of voice 29
Risks associated with developing a drug within a therapeutic class 29
Filings and approval 29
Sales forecasts and assumptions 29
Competitor Ratio Analysis 30
Maraviroc (Pfizer) 30
Novelty/rationale for mechanism of action 30
Proof of concept/clinical data 30
Management/clinical expertise 30
Competition within the marketplace/gaining share of voice 30
Risks associated with developing a drug within a therapeutic class 31
Filings and approval 31
Sales forecasts and assumptions 31
Competitor Ratio Analysis 32
MK-0518 (Merck & Co) 32
Novelty/rationale for mechanism of action 32
Proof of concept/clinical data 32
Management/clinical expertise 33
Competition within the marketplace/gaining share of voice 33
Risks associated with developing a drug within a therapeutic class 33
Filings and approval 33
Sales forecasts and assumptions 34
Competitor Ratio Analysis 34
Retapamulin (GlaxoSmithKline) 34
Novelty/rationale for mechanism of action 34
Proof of concept/clinical data 34
Management/clinical expertise 35
Competition within the marketplace/gaining share of voice 35
Risks associated with developing a drug within a therapeutic class 35
Filings and approval 35
Sales forecasts and assumptions 35
Competitor Ratio Analysis 36
Telbivudine (Novartis) 36
Novelty/rationale for mechanism of action 36
Proof of concept/clinical data 36
Management and clinical expertise 36
Competition within the marketplace/ gaining share of voice 37
Risks associated with developing a drug within a therapeutic class 37
Filings & Approvals 37
Sales forecasts and assumptions 37
Competitor Ratio Analysis 38
TMC-114 (Johnson & Johnson/Tibotec Pharma) 38
Novelty/rationale for mechanism of action 38
Proof of concept/clinical data 38
Management/clinical expertise 38
Competition within the marketplace/gaining share of voice 38
Risks associated with developing a drug within a therapeutic class 39
Filings and approval 39
Sales forecasts and assumptions 39
Competitor Ratio Analysis 40
Tygacil (Wyeth) 40
Novelty/rationale for mechanism of action 40
Proof of concept/clinical data 40
Management/clinical expertise 40
Competition within the marketplace/gaining share of voice 40
Risks associated with developing a drug within a therapeutic class 41
Filings and approval 41
Sales forecasts and assumptions 41
Competitor Ratio Analysis 41
Vicriviroc (Schering-Plough) 42
Novelty/rationale for mechanism of action 42
Proof of concept/clinical data 42
Management/clinical expertise 43
Competition within the marketplace/gaining share of voice 43
Risks associated with developing a drug within a therapeutic class 44
Filings and approval 44
Sales forecasts and assumptions 44
Competitor Ratio Analysis 45
VX-950 (Vertex Pharmaceuticals) 45
Novelty/rationale for mechanism of action 45
Proof of concept/clinical data 45
Management/clinical expertise 45
Competition within the marketplace/gaining share of voice 46
Risks associated with developing a drug within a therapeutic class 46
Filings and approval 46
Sales forecasts and assumption 47
Competitor Ratio Analysis 47
Zeven (Pfizer) 47
Novelty/rationale for mechanism of action 47
Proof of concept/clinical data 48
Management/clinical expertise 48
Competition within the marketplace/gaining share of voice 48
Risks associated with developing a drug within a therapeutic class 48
Filings and approval 49
Sales forecasts and assumptions 49
Competitor Ratio Analysis 49
COMPETITOR RATIO ANALYSIS SUMMARY 50
COMPETITOR RATIO ANALYSIS - COMPANIES 52
CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: jenniferc@cmsinfo.com
copyright © 2005 all rights reserved
For more information about us, visit CMSinfo.
